Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

amcenestrant (SAR439859)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Sanofi

Drug class:

Selective estrogen receptor degrader

Related drugs:

ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	SAR439859 Sensitive: C2 – Inclusion Criteria SAR439859 Sensitive : C2	SAR439859 Sensitive: C2 – Inclusion Criteria SAR439859 Sensitive : C2
ER Y537N	HER2 Negative Breast Cancer	ER Y537N	HER2 Negative Breast Cancer	SAR439859 Sensitive: C3 – Early Trials SAR439859 Sensitive : C3	SAR439859 Sensitive: C3 – Early Trials SAR439859 Sensitive : C3
ER D538G	HER2 Negative Breast Cancer	ER D538G	HER2 Negative Breast Cancer	SAR439859 Sensitive: C3 – Early Trials SAR439859 Sensitive : C3	SAR439859 Sensitive: C3 – Early Trials SAR439859 Sensitive : C3
ER Y537S	HER2 Negative Breast Cancer	ER Y537S	HER2 Negative Breast Cancer	SAR439859 Sensitive: C3 – Early Trials SAR439859 Sensitive : C3	SAR439859 Sensitive: C3 – Early Trials SAR439859 Sensitive : C3
ER mutation	HER2 Negative Breast Cancer	ER mutation	HER2 Negative Breast Cancer	SAR439859 Sensitive: C3 – Early Trials SAR439859 Sensitive : C3	SAR439859 Sensitive: C3 – Early Trials SAR439859 Sensitive : C3
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	palbociclib + SAR439859 Sensitive: C3 – Early Trials palbociclib + SAR439859 Sensitive : C3	palbociclib + SAR439859 Sensitive: C3 – Early Trials palbociclib + SAR439859 Sensitive : C3
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	letrozole + SAR439859 Sensitive: C3 – Early Trials letrozole + SAR439859 Sensitive : C3	letrozole + SAR439859 Sensitive: C3 – Early Trials letrozole + SAR439859 Sensitive : C3
ER Y537S	Estrogen Receptor Positive Breast Cancer	ER Y537S	Estrogen Receptor Positive Breast Cancer	SAR439859 Sensitive: D – Preclinical SAR439859 Sensitive : D	SAR439859 Sensitive: D – Preclinical SAR439859 Sensitive : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	palbociclib + SAR439859 Sensitive: D – Preclinical palbociclib + SAR439859 Sensitive : D	palbociclib + SAR439859 Sensitive: D – Preclinical palbociclib + SAR439859 Sensitive : D